Overview

Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

Status:
Recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.
Phase:
Phase 3
Details
Lead Sponsor:
Aridis Pharmaceuticals, Inc.
Treatments:
Anti-Bacterial Agents